Key Highlights

  • LABT shares trading down 14.58% today to $0.2027
  • Shares closed at $0.5775 on October 20, per third-party price data, before the IDWeek announcement
  • Phase 2a topline data for Nu-3 are expected in the first quarter of 2027
  • The stock listed on Nasdaq through a direct listing in April 2026
  • About 18.68 million shares are outstanding

Steep Slide Follows the IDWeek Presentation of Nu-3 Data

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) shares are trading down 14.58% today at $0.2027, in Penny Stock territory. No company-specific announcement was identified for today's decline.

The most recent news was an October 21 release on a poster presented at IDWeek 2026 in Washington. Third-party price data shows the stock closed at $0.5775 on October 20, so shares have fallen sharply since.

The company completed multikilogram Manufacturing of Nu-3 gel under cGMP standards, according to an earlier release. The drug has also drawn additional Patent coverage, including an Australian patent for related compounds.

Earlier this year, a May update on Nu-3 manufacturing progress also coincided with a steep one-day decline, per third-party price data, showing how reactive the shares have been to news flow.

Nu-3 Lab Data Highlight Broad Activity and Slow Resistance Buildup

The company describes Nu-3 as a broad-spectrum antimicrobial that showed rapid activity in laboratory tests against Gram-positive, Gram-negative and multidrug-resistant bacteria, as well as biofilms. These are company-reported in vitro results, not clinical outcomes.

In serial-passage testing, minimum inhibitory concentrations rose only slightly for S. aureus and E. coli, versus a 600-fold to 2,000-fold increase for the antibiotic ciprofloxacin.

The company framed the data as support for a national plan on antibiotic resistance discussed at a federal advisory council meeting in June. Antimicrobial resistance remains the central pitch for the program.

The company has described the compound as acting on bacterial membranes through a physical mechanism, which it says supports a high barrier to resistance. Clinical data in patients are still pending.

Clinical-Stage Antimicrobial Developer With a Phase 2a Trial Underway

Lakewood-Amedex is a clinical-stage biotechnology company developing locally delivered antimicrobials for infections and chronic wounds. Its lead candidate, Nu-3, is a gel for mildly infected diabetic foot ulcers and is aimed at drug-resistant bacteria such as MRSA and VRE.

The Phase 2a study is ongoing, with topline data expected in the first quarter of 2027. The company earlier reported that Nu-3 drug substance was stable for at least five years and the gel formulation for at least two years.

Third-party data lists a net loss of about $3.96 million and roughly 18.68 million shares outstanding. One third-party estimate puts Liquidity near $5 million and monthly burn near $1 million, which is not a company disclosure and could not be verified.

The company directly listed on Nasdaq in April 2026, so it has a short trading history and a wide historical price range.

The company has also selected a specialist contract research organization to lead the Phase 2 trial in diabetic foot ulcers.

Phase 2a Readout in the First Quarter of 2027 Is the Next Dated Event

With no disclosed trigger for today's move, the key milestone is the Nu-3 Phase 2a topline readout expected in early 2027. Financing needs ahead of that data are a point investors may watch.

The stock has been highly volatile since listing, and sub-dollar pricing leaves it sensitive to even small changes in volume.

Any dilutive financing, trial enrollment update or additional data release would be relevant for the shares, though none has been announced. Trading Volume and any financing news are also worth tracking.